Cancer Advisor

In a revealing post on X (formerly Twitter), whistleblower account @Jikkyleaks has shed light on four prominent universities that have quietly pursued patents and research on anti-parasitic medications—such as ivermectin, mebendazole, and fenbendazole—for treating various cancers. These drugs, long used to combat parasites in humans and animals, are now being explored for their potential anticancer properties.  The post, which credits AI assistant Grok for verifying the details, questions why this potentially game-changing information hasn't been more publicly disseminated. Drawing from the post and its sources, this article explores the universities involved, the science behind the drugs, and the broader implications. The Universities and Their Patent Pursuits According to the information compiled in the post, these institutions have been actively involved in patenting or researching these repurposed drugs. Here's a breakdown: University of British Columbia (UBC) The Universi...

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive biology, late diagnosis, and limited therapeutic options. Despite advances in multi-agent chemotherapy, the prognosis for metastatic disease remains poor. This review synthesizes current evidence on standard-of-care regimens, including NALIRIFOX and FOLFIRINOX, emerging targeted and immunotherapeutic approaches, and explores the potential repurposing of antiparasitic agents such as fenbendazole and ivermectin. We discuss recent clinical trials, safety profiles, and future directions for improving outcomes in stage 4 PDAC. Pancreatic Cancer Awareness Introduction Pancreatic cancer is among the most aggressive and therapeutically challenging malignancies, with a 5-year survival rate below 10% for all stages combined. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC) , which are frequently diagnosed at an advanced stage, limiting cura...